Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types

Treatment Name: FOLFOX + Panitumumab (Vectibix®)

FOLFOX + Panitumumab (Vectibix®) is a Chemotherapy Regimen for Colon Cancer

How does FOLFOX + panitumumab work?
Each of the medications in FOLFOX are designed to kill cancer cells. Panitumumab (an immunotherapy drug) is designed to bind to Epidermal Growth Factor Receptor (EGFR) on the surface of cancer cells, which shuts down one of the signals that tell the cancer cells to grow.

FOL – folinic acid (leucovorin)
F - fluorouracil
OX – Oxaliplatin
Panitumumab (Vectibix®)

Goals of therapy:
FOLFOX + panitumumab is a combination regimen of chemotherapy and immunotherapy. It is given to shrink tumors and help alleviate symptoms of colon cancer, and is not commonly given with the goal of cure.


Create your own Treatment Tracker

  • Folinic acid (Leucovorin) intravenous infusion (I.V.), given over two hours before fluorouracil on Day 1
  • Oxaliplatin I.V. given over two hours on Day 1. This is commonly given at the same time as folinic acid (Leucovorin)
  • Fluorouracil I.V. push, usually given over 3 to 5 minutes on Day 1
  • Fluorouracil continuous I.V. infusion (via home-infusion pump) over 46 hours beginning Day 1
  • Panitumumab I.V. infusion over 60 minutes on Day 1
    • If the first infusion is well tolerated, subsequent infusions may be given over 30 minutes
    • Large doses may need to be given over 90 minutes

Estimated total infusion time for this treatment:

  • Up to 4 hours for Day 1 of each cycle is spent at the infusion center
  • Infusion times are based on clinical studies, but may vary depending on doctor preference or patient tolerability. Pre-medications and intravenous (I.V.) fluids, such as hydration, may add more time

FOLFOX + panitumumab is usually given in an outpatient infusion center, allowing the person to go home afterwards where they will continue to receive their continuous infusion of fluorouracil via ambulatory pump (at home). It may be given in the hospital if someone is too sick or if an ambulatory pump is not available or want to be used.

FOLFOX + panitumumab is repeated every 14 days. Each 14-day period is known as one Cycle. Each cycle may be repeated until the treatment no longer works or until unacceptable side effects occur. Duration of therapy depends upon response, tolerability, and number of cycles prescribed.

Click here for the common FOLFOX + panitumumab starting doses.

Side Effects

In a multi-drug regimen, each medication has unique side effects. When these medicines are given together, drug-related side effects reported in clinical studies give the best estimate of what to expect. In clinical studies, the most commonly reported (Grade 3 & 4) FOLFOX + panitumumab side effects are shown here:

  • Low white blood cells [neutropenia] (42%)
  • Skin rash, redness, or blistering (36%)
  • Diarrhea (18%)
  • Nerve pain (16%)
  • Low blood potassium (10%)
  • Fatigue (9%)
  • Mouth sores (9%)
  • Low blood magnesium (6%)
  • Changes to fingernails (3%)
  • Blood clots in the lungs (3%)
  • Neutropenic fever (2%)
  • Infusion reaction (<1%)

Side effect videos Side Effect Videos
DiarrheaDiarrheaPainPainFatigue Fatigue Blood ClotsBlood ClotsNeutropenic FeverNeutropenic Fever


How often is monitoring needed?
Labs (blood tests) may be checked before each treatment. Labs often include: Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), blood magnesium, plus any others your doctor may order. CEA (carcinoembryonic antigen), a tumor marker, may be checked periodically.

How often is imaging needed?
Imaging may be checked before treatment and periodically during treatment. Imaging may include: magnetic resonance imaging (MRI), computerized tomography (CT) scans, or positron emission tomography (PET) scans.

How might blood test results/imaging affect treatment?
Depending upon the results, your doctor may advise to continue FOLFOX + panitumumab as planned, or delay or switch therapy.

Questions to Ask Your...

A better understanding of your treatments will allow you to ask more questions of your healthcare team. We then hope that with the answers, you will get better results and have greater satisfaction with your care. Because we know it's not always easy to know what questions to ask, we've tried to make it easy for you!

Choose any healthcare provider below to see common questions that you may want to ask of this person. Then, either print each list to bring to your clinic visits, or copy the questions and send them as a message to your healthcare team through your electronic medical record.

ChemoExperts Tips

  • Patients will have an infusion pump strapped to their body for 2 days to allow fluorouracil (5-FU) to continuously infuse into a vein. The I.V. line is connected at the end of the chemotherapy session by a nurse. When the 5-FU infusion is finished, the patient will have to go back to the infusion center or hospital to have it disconnected unless a home health nurse comes to the patient’s home to do this
  • Oxaliplatin can make you very sensitive to cold things such as cold drinks or cold weather for a few days after receiving treatment. It is best to wear warm clothes in cold weather and to not drink cold liquids, especially those with ice, or hold cold objects in your hands for up to 2 days after each oxaliplatin infusion
  • Fluorouracil may cause painful redness, blistering, and peeling skin reaction on the palms of your hands and on the soles of your feet. This is known as Hand-Foot Syndrome. Ways to help reduce the risk of experiencing Hand-Foot Syndrome include using a non-alcoholic moisturizer daily on your hands and feet, avoid wearing gloves, avoid prolonged exposure to hot water, and avoid activities that put pressure or friction on your hands and feet such as golf or tennis while receiving fluorouracil
  • Panitumumab may cause low blood magnesium and potassium. You may need to receive IV infusions of potassium or magnesium which may increase your time spent at the infusion center
  • Panitumumab may make your skin more sensitive to sunlight. When out in the sun during treatment and for up to 2 months after the last dose, be sure to use sunscreen and wear clothing and hats that will limit your exposure to sun as best as possible
  • Panitumumab may cause changes to fingernails and toenails such as redness, swelling, oozing, bleeding, cracking, discoloration, or ridges in the nails. This is known as “paronychia”. This can first develop weeks or months after starting therapy with panitumumab and can last for months after therapy is stopped. To help prevent paronychia from developing, avoid wearing tight fitting shoes or gloves and avoid putting unnecessary pressure or friction on fingernails and toenails. If you experience symptoms of paronychia, talk with your doctor as prescription corticosteroid creams or antibiotics may be needed
  • Clinical trials may exist for colon cancer. Ask your doctor if any studies are currently enrolling in your area. If not, go to to search for other centers offering study medications

Patient Assistance & Co-payment Coverage

Patients under the age of 65 years, or those with private insurance plans:
If you have insurance and are looking for patient assistance or copay assistance for FOLFOX + Panitumumab (Vectibix®), we have provided links that may help.

Visit our Patient Assistance page and click the links to various patient assistance programs for help paying for FOLFOX + Panitumumab (Vectibix®). Depending upon your income, they may be able to help cover the cost of:

  • Folinic acid
  • Fluorouracil
  • Oxaliplatin
  • Panitumumab

For Branded medications (may be available for generic medications too), check with the manufacturer to determine if a co-pay card is offered and if it could reduce your monthly copay.

  • If you are uninsured, check with the manufacturer to determine if you are eligible to receive medication at no cost.

Medicare and Medicaid patients (Patients 65 years or older):
The clinic providing treatment will likely pre-authorize medications and immune therapies such as FOLFOX + Panitumumab (Vectibix®) and are the best source to help you understand drug cost.

  • Ask to speak with a patient assistance technician or financial counselor at the clinic or hospital administering this therapy.

Emotional Wellness

What is Emotional Wellness?
Emotional wellness is having a positive outlook balanced with a realistic understanding of current life events. This requires both an awareness and acceptance of your emotions. It is with this knowledge that you can develop a plan to take the necessary actions to positively impact your life.

Emotional wellness uses an ongoing process to continually reflect on the stressors of life in a constructive manner to move forward and create happiness.

Because emotional wellness is deeply connected with physical, social, and spiritual wellness, pursuing it often becomes particularly difficult in times of major illness. Despite this difficulty, working toward emotional wellness has been connected to improved treatment outcomes and a higher likelihood of achieving goals of therapy.

Learn more about pursuing emotional wellness while receiving treatment with FOLFOX + Panitumumab (Vectibix®)

Individual Drug Label Information

Folinic acid (Leucovorin)

  • Folinic acid is an intravenous (I.V.) drug that is a derivative of folic acid, also known as vitamin B9
  • Is clear to slightly yellow in color
General Folinic Acid (Leucovorin) Side Effects
  • Seizures and fainting have been rarely reported
  • Click on the Folinic Acid (Leucovorin) package insert for all reported side effects and possible drug interactions
See DailyMed package insert.

Fluorouracil (Adrucil®)

  • Fluorouracil (5-FU) Is an intravenous (I.V.) drug
  • Recommended to be given only under the supervision of a qualified physician well versed in administering chemotherapy
General Fluorouracil (5-FU, Adrucil) Side Effects
  • Low white blood cell count (leucopenia and neutropenia)
  • Mouth and throat sores or ulcers (mucositis)
  • Diarrhea
  • Nausea and vomiting
  • Low red blood cell and platelet counts
  • Allergic reactions, rarely
  • Eye pain, light sensitivity, excess watering, visual changes
  • Headache
  • Skin conditions:  dryness, redness, tingling, light sensitivity, pain, swelling, loss of nails (hand-foot syndrome)
  • Dosage adjustments may be required for severe liver dysfunction
  • Click on the Fluorouracil (5-FU, Adrucil) package insert below for reported side effects and possible drug interactions

Side Effect Videos
Nausea and VomitingNausea and VomitingDiarrheaDiarrheaFatigue Fatigue PainPainNeutropenic FeverNeutropenic Fever

See DailyMed package insert.

Oxaliplatin (Eloxatin®)

  • Oxaliplatin is an intravenous (I.V.) drug
  • Allergic reactions have been reported and may occur within minutes. Certain drugs can be given to alleviate the symptoms: antihistamines, corticosteroids, or epinephrine
  • Oxaliplatin is usually diluted in a dextrose 5% I.V. bag and infused over 2 hours
  • Dosage adjustments may be required for liver dysfunction
General Oxaliplatin (Eloxatin) Side Effects
  • Nerve pain or tingling in feet and hands, loss of tendon reflexes
  • Oxaliplatin can make you very sensitive to cold things such as cold drinks or cold weather for a few days after receiving oxaliplatin. It is best to wear warm clothes in cold weather and to not drink cold liquids, especially those with ice, or hold cold objects in your hands for up to 2 days after each oxaliplatin infusion
  • Lung toxicity:  avoid with certain lung conditions
  • Low white blood cells, platelets, and red blood cells
  • Constipation
  • Diarrhea
  • Vomiting or nausea
  • Fatigue
  • Mouth sores
  • Change in liver function
  • Avoid during pregnancy, known to cause fetal harm
  • Click on the oxaliplatin (Eloxatin) package insert below for reported side effects and possible drug interactions

Side Effect Videos
Nausea and VomitingNausea and VomitingDiarrheaDiarrheaFatigue Fatigue ConstipationConstipationPainPain

See DailyMed package insert.

Panitumumab (Vectibix®)

  • Is an intravenous (I.V.) infusion
  • Skin toxicities happened with 90% of patients taking this immunotherapy drug
  • May make your skin more sensitive to sunlight. Use sunscreen and wear clothing and hats that will limit exposure to sun
  • Dosage adjustments may be required serious skin related side effects
  • Patients with skin or soft tissue toxicities should be monitored (watched) closely
  • May cause low blood magnesium and potassium. You may need to receive IV infusions of potassium or magnesium during treatment
  • Rarely causes eye toxicity: keratitis and ulcerative keratitis which can lead to corneal perforation
  • May cause fetal harm if given while pregnant. Females should use effective contraception during treatment and for at least 2 months after the last dose 
  • Women should not to breastfeed during treatment with Vectibix and for 2 months after the final dose 
General side effects from panitumumab
  • Skin rash, redness, acne lesions, itching, skin exfoliation (shedding), fissures,  dry skin or blistering
  • Diarrhea
  • Low blood potassium
  • Low blood magnesium
  • Dehydration
  • Changes to fingernails
  • Click on the panitumumab (Vectibix®) package insert link below for drug manufacturer reported side effects, possible drug interactions, and other panitumumab prescribing information

Side Effect Videos
Nausea and VomitingNausea and VomitingDiarrheaDiarrheaFatigue Fatigue PainPain

See DailyMed package insert.

Share this page:


Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-705.

Created: January 14, 2019 Updated: January 14, 2019

What is Colon Cancer?

A disease of the cells from the large intestine.  Colon cancer is the third most common cancer among both men and women.  Known causes include:  family history, poor diet, sedentary lifestyle, obestity, diabetes, history of colon polyps, smoking, heavy alcohol use, prior radiation treatment to abdomen for other cancers, and old age.  The stage can vary at diagnosis and throughout treatment.  Stages of colon cancer use Tumor, Node, Metastasis (TNM) staging as well as Stage Grouping using Stages 0, I, II, III, or IV.  More specific subytpes of the primary stages exist, for example Stage II may be further divided into stages IIa, IIb, or IIc, and stage subtype may effect treatment options. The effectiveness of the treatment may depend upon the stage at diagnosis.


NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose which therapy is appropriate for you.

What does Cure mean?

The word “cure” means there are no cancer cells left in the body and cancer will never come back. Depending on the cancer type and stage, this may be the true goal of therapy. However, it is very difficult to prove all cancer cells are gone. Even though images, like X-rays and MRI’s, and blood tests may not show any signs of cancer, there can be a small amount of cancer cells still left in the body. Because of this, the word “remission” is used more often. This means there are no signs or symptoms of cancer. Patients in remission are followed closely for any signs of cancer returning. Sometimes, more chemotherapy may be given while in remission to prevent the cancer from coming back.

Doctors usually do not consider a patient “cured” until the chance of cancer returning is extremely low. If cancer does return, it usually happens within 5 years of having a remission. Because of this, doctors do not consider a patient cured unless the cancer has not come back within 5 years of remission. The five-year cutoff does not apply to all cancers.

What is a CBC?

A Complete Blood Count (CBC) is a frequently ordered blood test that tells clinicians the status of your: 1) White blood cell count, 2) Hemoglobin, and 3) Platelet count at the time the test was taken.

Common uses:
1) White blood cell count (WBC): is used to determine infection risk, or response to chemotherapy. Certain chemotherapy agents may harm our good infection-fighting cells. Sometimes chemotherapy may need to be delayed to allow these cells to recover.

2) Hemoglobin: is used to determine if someone is anemic. Anytime the hemoglobin is below 12 g/dL, the person is said to be anemic. Red blood cell transfusions, and sometimes iron can be given to restore the hemoglobin level, but anemia treatment should always aim at treating the underlying cause or condition.

3) Platelet count: is used to determine if the risk of bleeding is increased or if a platelet transfusion is required to prevent bleeding. Certain medications that increase bleeding risk, such as: aspirin, certain chemotherapy agents, and blood thinners, may need to be stopped temporarily until the platelet count is within a safe range.

What is a CMP?

A Comprehensive Metabolic Panel (CMP) is a frequently ordered blood test that tells clinicians the status of your: 1) Electrolytes & Acid/Base status2) Kidney function, 3) Liver function, 4) Blood sugar, and 5) Calcium at the time the test was taken. It is commonly used to monitor liver and kidney function when beginning new medications such as chemotherapy. A total of 14 tests are run simultaneously and are shown below.

Electrolytes & Acid/Base status:
1) Sodium, 2) Potassium, 3) Carbon dioxide, 4) Chloride

Kidney Function:
5) BUN (blood urea nitrogen), 6) Serum creatinine (Scr)

Liver Function:
7) AST, 8) ALT, 9) Total bilirubin, 10) Alk Phos, 11) Albumin, 12) Total protein

Blood sugar:
13) Serum glucose

14) Serum calcium

Common Starting Doses

  • Folinic acid (Leucovorin) 400 mg/m2 intravenous infusion (I.V.) over 2 hours on Day 1
  • Oxaliplatin 85 mg/m2 I.V. given over two hours on Day 1
  • Fluorouracil 400 mg/m2 I.V. push over 3 to 5 minutes on Day 1
  • Fluorouracil 1200 mg/m2 continuous I.V. infusion over 46 hours beginning Day 1
  • Panitumumab 6 mg/kg I.V. infusion over 60 minutes on Day 1
    • If the first infusion is well tolerated, subsequent (later) infusions may be given over 30 minutes
    • Doses > 1000 mg to be given over 90 minutes